Hyperoxemic oxygen therapy in patients with acute anterior myocardial infarction: HOT-AAMI—design and rationale of a randomized trial
Study context
- Population
- Patients presenting with anterior ST-elevation myocardial infarction (STEMI) and undergoing successful percutaneous coronary intervention (PCI) of the left anterior descending arteryplanned enrolment (393 events required)
- Participants
- 1,266 patients
- Planned comparison
- SSO2 therapy on top of standard care vs standard of care alone
- Primary endpoint
- Composite of all-cause mortality or unplanned heart failure hospital admission or outpatient visit due to heart failure requiring intravenous diuretic therapy
- Follow-up
- 12-48 months
Methodological detailsdesign and rationale, 50 sites in Germany
- Design and rationale
- 50 sites in Germany
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Sample size calculation
- Relative reduction to detect in the primary composite endpoint
- 25%
- Expected yearly event rate in the control group
- 16%
- Mortality
- 7%
- Hospitalization for heart failure
- 5%
- Acute heart failure requiring outpatient treatment
- 4%
- Significance level (2-sided)
- 0.05
- Power
- 80%
- Required events
- 393
- Secondary endpoints include cardiovascular mortality, recurrent myocardial infarction, stroke, and quality of life
Original publication
Hyperoxemic oxygen therapy in patients with acute anterior myocardial infarction: HOT-AAMI—design and rationale of a randomized trial. Am Heart J. Published 21 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →